Using mixed tumors comprising 80% EGFRvIII+ and 20% EGFRvIII− tumor cells, CAR T-vax therapy in the presence of IFN-γ blockade led to loss of survival extension and elicited no complete responses (Figure 7A–B); similar results were obtained when IL-12 was blocked (Figure 7C–D). Here, IFNG is linked to neoplasm.